The Scientist - USA (2019-12)

Immune checkpoint inhibitors promote anti-tumor immune responses by enhancing T cell activity. Measuring the pharmacodynamic effects of these

drug types presents a challenge as both the immune and cancer cell populations must be separated and assessed individually. Using a quantitative

multiplex immunofluorescence assay (mIF) allows for in-depth cell phenotype characterization and spatial context. Researchers at Frederick National

Laboratory for Cancer Research developed a robust mIF assay with InSituPlex® technology to better investigate T cell activation states within the tumor

microenvironment and across multiple patient tumor biopsies.

In this webinar, sponsored by Ultivue, Kristin Fino of Leidos Biomedical Research, for the National Cancer Institute at Frederick, will present the obstacles

associated with developing biomarker strategies and a multiplex immunofluorescence solution that improved the assessment of tumor/immune interactions.

SEAN DOWNING,PhD, MBA

Director, Customer Engagement 

Ultivue

KRISTIN FINO,PhD

Scientist

Leidos Biomedical Research, Inc.,

for the National Cancer Institute, Frederick

FRIDAY, NOVEMBER 1

2:30 - 4:00 PM EASTERN TIME

WATCH NOW!

http://www.the-scientist.com/

multiplexedimmunofluorescence-ultivue

TOPICS TO BE COVERED:

• Introduction to the InSItuPlex® technology


• Development of a multiplex panel for the quantitative
  assessment of T cell activation in relation to tumor cells


• Analyzing biomarker and cell phenotype trends across
  tumor types

WEBINAR SPONSORED BY:

ONDEMAND

Battling Bugs:

Mitigating Cell Culture Contamination

ONDEMAND

Investigating Targeted CD3 Activation in Cytotoxic T

Cells via Immune Checkpoint Inhibition with an Advanced

Multiplex Immunofluorescence Assay

WEBINAR SPONSORED BY:

Ensuring cell culture sterility is essential in small and large bioprocesses. Microbial contamination from bacteria, viruses, and fungi can spread among

experiments and workflows—wasting time, resources, and precious cell lines. These unwanted organisms can change the growth rate, morphology,

and gene expression of cultured cells. Additionally, contaminants in biotherapeutics put patients at risk. Therefore, methods to prevent and remove

contaminants should be a main consideration for every lab. The Scientist is bringing together experts from industry to discuss issues with cell culture

contamination on small and large scales. In this webinar, sponsored by Sartorius, experts will highlight the effects of contaminants, examine

prevention and mitigation strategies for unwanted microbial growth, and answer questions from attendees.

BARBARA J. POTTS,PhD

Senior Consultant

Potts and Nelson Consulting

THURSDAY, NOVEMBER 7

2:30 - 4:00 PM EASTERN TIME

WATCH NOW!

http://www.the-scientist.com/battling-bugs

NICK AMISS

Product Steward, Oxford Biomedica

Science Outreach Speaker

TOPICS TO BE COVERED:

• The risks and prevention of microbial contamination in
  recombinant protein, cell, and gene therapy products


• Mycoplasma: the smallest bug, the biggest problem